MED-EL research initiatives are driven by advances in our technology. At the same time, each new research initiative contributes to the knowledge base required to create innovative new technologies. The benefits of these contributions are continuously being evaluated in order to maximise their performance for the hearing implant recipient. These initiatives fuel the development of new products and features that ensures the company’s dynamic future.
The efficacy of atraumatic insertion is best evaluated in terms of the preservation of residual hearing. Preservation of some or complete residual hearing after a full electrode insertion demonstrates the quality of the device and the surgical technique. This preservation is currently the best functional measure available to assess the trauma (or lack thereof) caused by electrode insertion.
MED-EL has pioneered research in the field of tinnitus reduction through cochlear implants. Tinnitus is the disturbing perception of noises of different frequencies and intensities in the absence of corresponding sound stimuli. Chronic tinnitus often adversely affects an individual’s quality of life and can interfere with normal audition.
Intra-Cochlear Drug Delivery
MED EL has pioneered the advancement of intra-cochlear drug delivery since 1999. The aim of this long-term research initiative is to improve hearing quality and general outcomes for all implant recipients.
ART is the name for MED-EL’s method for gaining Evoked Compound Action Potential (ECAP) measurements. ART, or Auditory Nerve Response Telemetry, is useful for providing objective data about patient stimulation both intraoperatively and during fitting.